Shares of Iridex IRIX were flat after the company reported Q1 results.
Earnings per share decreased 16.67% year over year to ($0.14), which were in line with the estimate of ($0.14).
Revenue of $11,959,000 rose by 32.57% year over year, which beat the estimate of $9,900,000.
Iridex hasn't issued any earnings guidance for the time being.
The upcoming fiscal year's revenue expected to be between $48,000,000 and $51,000,000.
Details Of The Call
Date: May 11, 2021
Time: 05:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/z5eucr6w
52-week high: $9.71
52-week low: $1.46
Price action over last quarter: down 2.16%
IRIDEX Corp is involved in the business of developing, manufacturing and marketing laser-based medical systems, delivery devices and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, service and support activities. The geographical segments of the company include the United States, Europe, the Americas, excluding the U.S and Asia/Pacific Rim.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.